This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Selegiline
A selective MAO-B inhibitor (Deprenyl/Emsam) used for Parkinson's disease and depression that doubles as a neuroprotective nootropic - boosting dopamine, phenylethylamine, and neurotrophic factors whilst increasing antioxidant enzyme activity and potentially extending lifespan.
Benefits
What is Selegiline?
Selegiline (L-deprenyl) is an irreversible, selective monoamine oxidase type B (MAO-B) inhibitor originally developed for Parkinson's disease and later approved as a transdermal patch (Emsam) for major depressive disorder. At low oral doses of 1-5 mg, selegiline selectively inhibits MAO-B without significantly affecting MAO-A, preserving the metabolism of serotonin and norepinephrine whilst dramatically boosting dopamine and phenylethylamine (PEA) levels in the brain. This selectivity is key to its nootropic profile - enhanced dopaminergic tone supports motivation, focus, and cognitive clarity without the dietary restrictions (the "cheese effect") associated with non-selective MAO inhibition.
Selegiline has earned a reputation as the quintessential "anti-ageing nootropic" based on the pioneering work of Professor Joseph Knoll at Semmelweis University in Budapest. Knoll's research, published across multiple studies from the 1980s through the 2000s, demonstrated that low-dose selegiline extended mean and maximum lifespan in rats by approximately 40%, enhanced sexual performance and cognitive function in aged animals, and increased the activity of endogenous antioxidant enzymes including superoxide dismutase (SOD) and catalase. A 2006 meta-analysis in the Journal of Neural Transmission confirmed neuroprotective effects independent of MAO-B inhibition, including increased expression of neurotrophic factors such as BDNF, GDNF, and NGF, anti-apoptotic effects via upregulation of Bcl-2 and downregulation of Bax, and enhancement of antioxidant defences. These properties make selegiline uniquely positioned at the intersection of cognitive enhancement, neuroprotection, and longevity science.
- Selective MAO-B inhibition: Irreversibly inhibits monoamine oxidase B, preventing the breakdown of dopamine and phenylethylamine in the brain. At low doses (1-5 mg), selectivity for MAO-B is maintained, avoiding interference with MAO-A-dependent serotonin and norepinephrine metabolism
- Dopamine enhancement: Increases synaptic dopamine availability by blocking its enzymatic degradation, supporting motivation, reward processing, motor function, and executive cognition
- Phenylethylamine elevation: Dramatically increases PEA levels - an endogenous trace amine that enhances dopamine and norepinephrine release, contributing to alertness, mood elevation, and cognitive drive
- Neurotrophic factor upregulation: Increases expression of BDNF, GDNF (glial cell line-derived neurotrophic factor), and NGF (nerve growth factor), promoting neuronal survival, growth, and synaptic plasticity
- Antioxidant enzyme induction: Upregulates superoxide dismutase (SOD) and catalase activity, enhancing the brain's endogenous antioxidant defence systems against oxidative damage
- Anti-apoptotic effects: Increases Bcl-2 (anti-apoptotic) and decreases Bax (pro-apoptotic) gene expression, protecting neurons from programmed cell death independent of MAO-B inhibition
- Nootropic/neuroprotective dose: 1-5 mg per day orally or sublingually. This range provides selective MAO-B inhibition and neurotrophic benefits without significant MAO-A involvement
- Sublingual administration: 1-2.5 mg sublingually bypasses first-pass metabolism, increasing bioavailability approximately 4-fold and reducing amphetamine metabolite production
- Parkinson's dose: 5-10 mg per day (the standard clinical dose), though selectivity for MAO-B begins to decrease above 10 mg
- Transdermal patch (Emsam): 6-12 mg/24hr patches for depression - bypasses first-pass hepatic metabolism entirely
- Timing: Take in the morning or early afternoon. Evening dosing may cause insomnia due to dopaminergic and stimulant metabolite effects
- Cheese effect threshold: At nootropic doses of 1-5 mg, the risk of tyramine-induced hypertensive crisis is negligible because MAO-A in the gut remains functional. Dietary restrictions are only necessary at doses exceeding 20 mg orally
- Amphetamine metabolites: Oral selegiline produces small amounts of L-methamphetamine and L-amphetamine as metabolites, which may cause insomnia or anxiety in sensitive individuals. Sublingual dosing significantly reduces this issue
- Drug interactions: Do not combine with SSRIs, SNRIs, tricyclic antidepressants, meperidine, tramadol, or dextromethorphan due to risk of serotonin syndrome. Avoid other dopaminergic drugs without medical supervision
- Common side effects: Insomnia, dry mouth, dizziness, and nausea are the most frequently reported at clinical doses. Most side effects are dose-dependent and uncommon at low nootropic doses
- Cardiovascular: Monitor blood pressure when initiating therapy. Orthostatic hypotension may occur, particularly in elderly patients or those taking antihypertensive medications
Natural Sources & Forms
- Prescription tablets (Eldepryl/Zelapar): 5 mg tablets for Parkinson's disease, available by prescription worldwide
- Transdermal patch (Emsam): 6 mg, 9 mg, and 12 mg/24hr patches approved for major depressive disorder in the US
- Orally disintegrating tablets (Zelapar): 1.25 mg tablets designed for buccal absorption, reducing first-pass metabolism
- Research chemical sources: Available from nootropic vendors as powder or capsules, though pharmaceutical-grade products are preferred for consistent dosing
- Liquid formulations: Some compounding pharmacies prepare liquid selegiline for precise low-dose titration
Frequently Asked Questions
A selective MAO-B inhibitor (Deprenyl/Emsam) used for Parkinson's disease and depression that doubles as a neuroprotective nootropic - boosting dopamine, phenylethylamine, and neurotrophic factors whilst increasing antioxidant enzyme activity and potentially extending lifespan.
The key benefits of Selegiline include: Cognitive Enhancement, Energy, Focus, Libido, Longevity, Mood, Motivation.
Selective MAO-B inhibition: Irreversibly inhibits monoamine oxidase B, preventing the breakdown of dopamine and phenylethylamine in the brain. At low doses (1-5 mg), selectivity for MAO-B is maintained, avoiding interference with MAO-A-dependent serotonin and norepinephrine metabolism Dopamine enhancement: Increases synaptic dopamine availability by blocking its enzymatic degradation, supporting motivation, reward processing, motor function, and executive cognition Phenylethylamine elevation: Dramatically increases PEA levels - an endogenous trace amine that enhances dopamine and norepinephrine release, contributing to alertness, mood elevation, and cognitive drive Neurotrophic factor upregulation: Increases expression of BDNF, GDNF (glial cell line-derived neurotrophic factor), and NGF (nerve growth factor), promoting neuronal survival, growth, and synaptic plasticity Antioxidant enzyme induction: Upregulates superoxide dismutase (SOD) and catalase activity, enhancing the brain's endogenous antioxidant defence systems against oxidative damage Anti-apoptotic effects: Increases Bcl-2 (anti-apoptotic) and decreases Bax (pro-apoptotic) gene expression, protecting neurons from programmed cell death independent of MAO-B inhibition
Nootropic/neuroprotective dose: 1-5 mg per day orally or sublingually. This range provides selective MAO-B inhibition and neurotrophic benefits without significant MAO-A involvement Sublingual administration: 1-2.5 mg sublingually bypasses first-pass metabolism, increasing bioavailability approximately 4-fold and reducing amphetamine metabolite production Parkinson's dose: 5-10 mg per day (the standard clinical dose), though selectivity for MAO-B begins to decrease above 10 mg Transdermal patch (Emsam): 6-12 mg/24hr patches for depression - bypasses first-pass hepatic metabolism entirely Timing: Take in the morning or early afternoon. Evening dosing may cause insomnia due to dopaminergic and stimulant metabolite effects
Cheese effect threshold: At nootropic doses of 1-5 mg, the risk of tyramine-induced hypertensive crisis is negligible because MAO-A in the gut remains functional. Dietary restrictions are only necessary at doses exceeding 20 mg orally Amphetamine metabolites: Oral selegiline produces small amounts of L-methamphetamine and L-amphetamine as metabolites, which may cause insomnia or anxiety in sensitive individuals. Sublingual dosing significantly reduces this issue Drug interactions: Do not combine with SSRIs, SNRIs, tricyclic antidepressants, meperidine, tramadol, or dextromethorphan due to risk of serotonin syndrome. Avoid other dopaminergic drugs without medical supervision Common side effects: Insomnia, dry mouth, dizziness, and nausea are the most frequently reported at clinical doses. Most side effects are dose-dependent and uncommon at low nootropic doses Cardiovascular: Monitor blood pressure when initiating therapy. Orthostatic hypotension may occur, particularly in elderly patients or those taking antihypertensive medications
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!